[Emmaus Life Sciences, Inc.] Emmaus Life Sciences, Inc. announced that it has entered into an exclusive option agreement with Cedars-Sinai to continue investigating the clinical utility of L-glutamine oral powder in combination with chemotherapy as a potential treatment for PDAC.